Phase II Study of First-line Amrubicin in Elderly Patients with Extensive Disease Small-Cell Lung Cancer (CJLSG1104)

Trial Profile

Phase II Study of First-line Amrubicin in Elderly Patients with Extensive Disease Small-Cell Lung Cancer (CJLSG1104)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2015

At a glance

  • Drugs Amrubicin (Primary) ; Granulocyte colony-stimulating factors
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Dec 2015 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
    • 15 Jan 2013 New trial record
    • 07 Jan 2013 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top